DUKE STREET BIO - Key Persons
Job Titles:
- Senior Advisor, New Enterprise Associates Co - Chair SAB, Amgen Former CSO, Bristol Myers Squibb
Job Titles:
- Co - Founder and Former / Chief Scientific Officer
Job Titles:
- Chief Drug Development Scientist, CRUK
Job Titles:
- CSO, Apricity Health Former Executive Director, Oncology Discovery
Job Titles:
- Chief Medical Officer
- Physician
Dónal Landers is a highly experienced pharmaceutical physician with a proven track record of leading multiple molecules through early oncology clinical development. Dr Landers combines science, medicine with an entrepreneurial flair to drive translational and clinical drug development in oncology.
After obtaining his primary medical degree from Trinity College, Dublin, Dónal spent several years practicing hospital clinical medicine. He undertook an MBA at University College Dublin before transitioning to senior management at St. James's Hospital. Dónal then co-founded his own health informatics company developing ‘patient-centric' mobile technology solutions, enabling patients to collect and monitor their own health data.
Dónal was also co-founder and Strategic Director of the Digital Experimental Cancer Medicine Team based at Cancer Research UK Manchester Institute. This research team was setup to provide next generation patient cancer care using data-driven evidence to enable the transformation of clinical decision-making.
Job Titles:
- Head of Clinical Operations
Dr. Jeff Thompson, PhD, MBA brings a wealth of experience spanning over three decades in the Pharma and Biotech Industries, and has an impressive record of taking molecules from preclinical research through to clinical development.
Jeff obtained his BSc in Biochemistry from Liverpool Polytechnic, followed by a PhD in Cell Biology/Biochemistry at Victoria University of Manchester. Further complementing his scientific background, Jeff completed an MBA at Henley Management College. Jeff most recently served as a Senior Director of Clinical Programs at AstraZeneca UK, where he successfully oversaw a portfolio of clinical studies for various oncology targets.
Before AstraZeneca, he was the Vice President of Clinical Operations at Inflazome UK, where he led the operations to transition pre-clinical assets into clinical development. Under his leadership, Inflazome successfully navigated two assets through First in Human (FTIH) studies, contributing to the company's acquisition by Roche in 2021.
Job Titles:
- Director, Immunotherapy and Drug Development Center, UPMC Hillman Cancer Center and University of Pittsburgh
Job Titles:
- Professor, Department of Nutrition / University of Oslo, Department of Pharmacology & Toxicoloty / University of Toronto
Job Titles:
- Professor of Experimental Cancer Therapeutics
Job Titles:
- Professor of Experimental
Job Titles:
- Medical Director, Institute for Applied Cancer Science